Fair Prescription Drug Prices for Americans Act

The Fair Prescription Drug Prices for Americans Act would cap the U.S. retail price of prescription drugs and biological products at the average price in Canada, France, Germany, Italy, Japan, and the United Kingdom. Drug manufacturers must annually report their prices in the U.S. and these six countries, with the government calculating the average price for each drug. Manufacturers exceeding the cap would face a civil penalty of 10 times the price difference per unit sold. This bill directly affects drug manufacturers selling in the U.S. market, aiming to align U.S. drug pricing with international averages.